Role of Compounding Pharmacies in Sating Appetite for GLP-1s
Powered by ![]()
All the vital news, analysis, and commentary curated by our industry experts.
Against the backdrop of a global surge in demand for drugs based on the GLP-1 receptor agonists (GLP-1 RAs), semaglutide and tirzepatide, compounding pharmacies have come to the fore. This is not only for their traditional role of providing personalized dosing, but also because of their role in helping combat shortages and their ability to provide low-priced alternatives to originator brands. In some countries, this has led to increased scrutiny in terms of the quality of compounded versions, as well as questions over whether they infringe upon the intellectual property of patented brands. In this Strategic Report, GlobalData throws light on the latest trends in terms of compounding GLP-1s and examines how originator companies have been responding to this source of competition.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Obesity reports